Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gancher, S. T.
Right arrow Articles by Woodward, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gancher, S. T.
Right arrow Articles by Woodward, W. R.
NEUROLOGY 1987;37:940
© 1987 American Academy of Neurology

Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients

Stephen T. Gancher, MD, John G. Nutt, MD and William R. Woodward, PhD

Departments of Neurology (Drs. Gancher, Nutt, and Woodward), Pharmacology (Dr. Nutt), and Biochemistry (Dr. Woodward), Oregon Health Sciences University, Portland, OR.

We compared the pharmacokinetics of oral and IV infusions of levodopa in untreated, stable, and fluctuating patients pretreated with carbidopa. After oral dosing, mean peak plasma levodopa levels, time to peak level concentration after oral levodopa, and area under the curve were similar in all groups. Absorption was proportional to dose. Plasma elimination half-lives, clearance rates, and volumes of distribution after levodopa infusions were similar in all groups. 3–0-Methyldopa levels were similar in stable and fluctuating subjects. We conclude that the peripheral pharmacokinetics of levodopa do not differ between untreated, stable, and fluctuating patients, and that altered peripheral kinetics of the drug are unlikely to explain the development of the fluctuating state.

Address correspondence and reprint requests to Dr. Gancher, Department of Neurology, Oregon Health Sciences University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97201.

Supported in part by the N.L. Tartar Research Fund, NINCDS NS07759–02 and R01NS21062–03, and Clinical Research Center Grant 5-M01-RR00334–20.

Received June 13, 1986. Accepted for publication in final form September 19, 1986.




This article has been cited by other articles:


Home page
 Arch NeurolHome page
Parkinson Study Group
A Randomized Controlled Trial of Etilevodopa in Patients With Parkinson Disease Who Have Motor Fluctuations
Arch Neurol, February 1, 2006; 63(2): 210 - 216.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. S. Lee, H. S. Kim, E. K. Cho, J. H. Lim, and J. O. Rinne
COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease
Neurology, February 26, 2002; 58(4): 564 - 567.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
B. Herer, I. Arnulf, and B. Housset
Effects of Levodopa on Pulmonary Function in Parkinson's Disease
Chest, February 1, 2001; 119(2): 387 - 393.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. B. Calne
Treatment of Parkinson's Disease
N. Engl. J. Med., September 30, 1993; 329(14): 1021 - 1027.
[Full Text]

Home page
 Arch NeurolHome page
J. G. Nutt, W. R. Woodward, J. H. Carter, and S. T. Gancher
Effect of Long-term Therapy on the Pharmacodynamics of Levodopa: Relation to On-Off Phenomenon
Arch Neurol, November 1, 1992; 49(11): 1123 - 1130.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
R. Kurlan
Dietary Therapy for Motor Fluctuations in Parkinson's Disease
Arch Neurol, November 1, 1987; 44(11): 1119 - 1121.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by AAN Enterprises, Inc.